麻豆传媒

Patients with complete response can have long treatment-free interval, study suggests

More than 40% of adults, half of children met response criteria, majority of responses durable

News, features, and commentary about cancer-related issues

But absence of significant OS benefit raises questions about long-term benefit, expert says

Improvements seen in pain, neuropathy, and cognitive function

Delegates express concerns that PPE doesn't always cover women, who are more at risk of exposure

Health news and commentary gathered by 麻豆传媒 staff

And nearly half of responders to enfortumab vedotin plus pembrolizumab remained in remission

News, features, and commentary about cancer-related issues

Health news and commentary gathered by 麻豆传媒 staff

PD-1/PD-L1 inhibitors singled out for association

Some races still too close to call

Momentum grows for earlier intervention, including pre-fibrotic disease

Selected highlights from the 2024 American College of Gastroenterology annual meeting